FDG Positron Emission Tomography (PET) for 9 Cancers (brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder and kidney

CMS evidence review | evidence_type=MEDCAC Meeting | record_type=medcac_meeting | document_id=44 | meeting_date=2008-08-20

This meeting will focus on the oncologic indications of 2-[F-18] Fluoro-D-Glucose (FDG) positron emission tomography (PET) for nine cancers (brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder and kidney). The panel will review the scientific evidence of the impact of PET as part of a management strategy to improve patient-centered outcomes. The panel will also consider data generated in accordance with a prior national coverage determination to cover PET for specified cancers when additional data are prospectively collected.

Actions Taken: August 1, 2008 Posted FR notice announcing meeting and Questions to panel. August 14, 2008 Posted Agenda and Roster . August 15, 2008 Posted Technology Assessment . August 27, 2008 Posted scoresheet [PDF, 369KB] from meeting. September 26, 2008 Posted Minutes [PDF, 20KB] and Transcript [PDF, 840KB]. Agenda: Federal Register Notice Agenda Medicare Evidence Development & Coverage Advisory Committee August 20, 2008 7:30 AM - 4:30 PM CMS Auditorium Saty Satya-Murti, MD, FAAN , Acting Chair Steve E. Phurrough, MD, MPA , Coverage and Analysis Group Maria Ellis , Executive Secretary 7:30 - 8:00 AM Registration 8:00 - 8:15 AM Opening Remarks— M. Ellis / Steve E. Phurrough, MD, MPA / Saty Satya-Murti, MD, FAAN 8:15- 8:55 AM CMS Presentation & Voting Questions - Stuart Caplan, RN, MAS 8:55 - 9:40 AM TA Presentation: Maria Beatriz Ospina, MSc, and Karen Yvonne Gulenchyn, MD, Evidence Based Practice Center in Edmonton, Alberta Canada 9:40 - 10:05 AM Bruce Hillner, Professor, Department of Internal Medicine, MVC Campus, Virginia Commonwealth University 10:05 - 10:30 AM David Mankoff, MD, PhD, Seattle, Washington, ACR, ASTRO, AMI, SNM 10:30 - 10:45 AM BREAK 10:45 -11:15 AM Scheduled Public Comments (Refer to Speaker List) ****************************************************************************** Public attendees, who have contacted the executive secretary prior to the meeting, will address the panel and present information relevant to the agenda. Speakers are asked to state whether or not they have any financial involvement with manufacturers of any products being discussed or with their competitors and who funded their travel to this meeting. ****************************************************************************** 11:15 - 11:35 AM Open Public Comments 11:35 - 12:35 PM LUNCH (on your own) 12:35 -1:35 PM Questions to Presenters 1:35 - 2:45PM Initial Open Panel Discussion: Dr. Satya-Murti 2:45 - 3:30 PM Formal Remarks and Voting Questions The Chairperson will ask each panel member to state his or her position on the voting questions 3:30 - 4:25 PM Final Open Panel Discussion: Dr. Satya-Murti 4:25 - 4:30 PM Closing Remarks/Adjournment: Dr. Phurrough & Dr. Satya-Murti 4:30 PM ADJOURN Issue: This meeting will focus on the oncologic indications of 2-[F-18] Fluoro-D-Glucose (FDG) positron emission tomography (PET) for nine cancers (brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder and kidney). The panel will review the scientific evidence of the impact of PET as part of a management strategy to improve patient-centered outcomes. The panel will also consider data generated in accordance with a prior national coverage determination to cover PET for specified cancers when additional data are prospectively collected. Minutes: Download Minutes [PDF, 20KB]. Other Material: Transcript 1 Panel Voting Questions: Use the following scale response for each of the questions below. 1 – 2 – 3 – 4 – 5 No Equivocal High Confidence Confidence 1. How confident are you that the evidence is adequate to conclude that FDG-PET imaging improves physician decision making when used for the following indications for each in these nine cancers? Diagnosis Staging Restaging Monitoring Bladder Brain Cervix Kidney Ovary Pancreas Prostate Small Cell Lung Testis 2. How confident are you that the evidence is adequate to conclude that FDG-PET imaging improves patient oriented clinical outcomes when used for the following indications in each of these nine cancers? Diagnosis Staging Restaging Monitoring Bladder Brain Cervix Kidney Ovary Pancreas Prostate Small Cell Lung Testis 3. How confident are you that these conclusions are generalizable to other cancers? 4. How confident are you that these conclusions are generalizable to non-research PET facilities in the general community? 5. How confident that these conclusions are generalizable to the Medicare beneficiary population? Download scoresheet [PDF, 369KB] Roster: Saty Satya-Murti, MD, FAAN, Acting Chair Health Policy Consultant I Craig Henderson, MD Adjunct Professor of Medicine University of California, San Francisco Nora A. Janjan, MD Professor, Dept of Radiation Oncology University of Texas M.D. Anderson Cancer Center J. Leonard Lichtenfeld, MD American Cancer Society Andrew Sloan, MD Staff Neurosurgeon Department of Neurosurgery University Hospitals of Cleveland Michael Steinberg, MD Professor and Chair Department of Radiation Oncology David Geffen School of Medicine at UCLA Sean D. Sullivan, PhD Professor of Pharmacy Public Health and Medicine Director Pharmaceutical Outcomes and Research and Policy Program University of Washington Consumer Representative Linda A. Bergthold, PhD Independent Consultant & Researcher Industry Representative Peter Juhn, MD, MPH President Therapeutic Resource Centers Medco Health Solutions, Inc. Guest Panel Member Richard L. Wahl, MD Professor of Radiology and Oncology Henry N. Wagner, Jr. Professor of Nuclear Medicine Director Nuclear Medicine/PET Facility Vice Chair Radiology for Technology and Business Development Johns Hopkins University School of Medicine Guest Speakers Bruce Hillner, MD Professor Department of Internal Medicine MVC Campus Virginia Commonwealth University David Mankoff, MD, PhD Seattle, Washington CMS Liasion Steve E. Phurrough, MD, MPH Director Coverage and Analysis Group Executive Secretary Maria A. Ellis